JCI Insight Preclinical Study Shows Five-Day E-Cigarette Exposure Damages Distal Lung Barrier and Suppresses Antiviral Genes

Researchers at National Jewish Health exposed cultured human distal lung cells and precision-cut lung slices to e-cigarette vapor, then measured barrier integrity, autophagy markers, cell viability, and immune gene expression. Separate arms added respiratory virus challenge, including SARS-CoV-2. Within one day, vapor disrupted tight junctions, raised stress signaling, slowed repair, and increased apoptosis; Th1 antiviral transcripts remained suppressed and viral titers rose after the exposure window closed. These changes occurred without combustion byproducts, isolating vapor components as the driver.

The findings align with observational data linking vaping to higher respiratory infection rates in young adults and extend mechanistic insight from earlier in-vitro work on bronchial cells. Unlike large cohort studies that cannot isolate exposure duration or site of injury, this controlled tissue model demonstrates that distal lung regions—critical for gas exchange—are affected rapidly and retain functional deficits after cessation. Funding came from NIH grants without reported industry ties.

Longitudinal human studies are now required to test whether brief vaping episodes predict clinically significant infection risk or early emphysema-like remodeling. Regulatory agencies should weigh these tissue-level signals when setting flavor and nicotine limits, while cessation programs must emphasize that even short use carries measurable biologic cost.